Bevacizumab Alone Versus Dose-dense Temozolomide Followed by Bevacizumab for Recurrent Glioblastoma, Phase III (RE-GEND)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02761070 |
|
Recruitment Status :
Recruiting
First Posted : May 4, 2016
Last Update Posted : September 1, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Glioblastoma Recurrence Progression | Drug: Temozolomide Drug: Bevacizumab | Phase 3 |
Glioblastoma (GBM), the most frequent malignant primary brain tumor, has yet been incurable despite recent progress on its standard of care using TMZ as the main trunk of initial therapy in the newly diagnosed setting. One of the main reasons accounting for the dismal prognosis would attribute to lack of active therapeutic regimens at recurrence.
Bevacizumab, a humanized monoclonal antibody against cardinal angiogenic factor vascular endothelial growth factor (VEGF), has recently shown efficacy for recurrent GBM, and has been approved in Japan, thereby being a standard care for recurrent GBM. Since there is no effective drugs or regimens developed at bevacizumab failure, insertion of another active drug prior to bevacizumab induction would enhance survival time for patients with recurrent GBM.
In Japan, there are currently only few chemotherapeutic agents approved and available for GBM. Among them rechallenge with alternating dosing of TMZ have shown certain efficacy with acceptable toxicities for patients with TMZ-pretreated recurrent GBM, thus being a good candidate for the regimen used prior to bevacizumab at recurrence.
The present proposal of sequential administration of dose dense TMZ (7/14d) followed by bevacizumab wishes to define a new standard of care for recurrent disease and hopes to identify the subgroups of patients with progressive or recurrent glioblastoma that respond particularly well to dose-dense temozolomide regimens.
This study is carried out as a JCOG Brain Tumor Study Group multicenter randomized phase III trial under approval by Advanced Medical Care B system, Ministry of Health, Labour and Welfare, Japan.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 146 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | A Multicenter Randomized Phase III Study for Recurrent Glioblastoma Comparing Bevacizumab Alone With Dose-dense Temozolomide Followed by Bevacizumab (JCOG1308C, RE-GEND-pIII) |
| Actual Study Start Date : | July 11, 2016 |
| Estimated Primary Completion Date : | July 10, 2024 |
| Estimated Study Completion Date : | July 10, 2024 |
| Arm | Intervention/treatment |
|---|---|
|
Active Comparator: Bevacizumab (BEV) alone
Bevacizumab 10 mg/kg, day 1 div, every 2 weeks
|
Drug: Bevacizumab
Other Name: Avastin |
|
Experimental: Dose Dense Temozolomide Followed by BEV
Temozolomide (120 mg/m2, po, 7 days on/7 days off, every 2 weeks per cycle) up to 48 cycles. The dose will be escalated to 150 mg/m2 at 3rd cycle if the defined conditions are met throughout the first 2 cycles. At recurrence or progression, bevacizumab alone(10 mg/kg, day 1 div, every 2 weeks)
|
Drug: Temozolomide
Other Names:
Drug: Bevacizumab Other Name: Avastin |
- Overall survival [ Time Frame: Time to event. Up to 2 years from the last patient in. ]Overall survival will be measured from registration until death for any reason. If the patient is alive at last follow-up, the patient will be censored at the last time of confirmation of survival.
- Progression-free survival (PFS) [ Time Frame: Time to event. Up to 2 years from the last patient in. ]Progression free will be measured from registration until the first occurrence of progression or death.
- 6-month progression-free survival (6m-PFS) [ Time Frame: 6 months from registration ]Number of patients without progression at 6 months from registration divided by number of all registered
- Complete response rate [ Time Frame: Through study completion, an average of 1 year ]Complete response rate is defined as the rate of complete response after chemotherapy in cases with measurable lesions through completion/termination of the protocol treatment.
- Response rate [ Time Frame: Through study completion, an average of 1 year ]Response rate is defined as the rate of complete response/partial response after chemotherapy in cases with measurable lesions through completion/termination of the protocol treatment.
- Adverse events [ Time Frame: Up to 1 year after completion/termination of the protocol treatment. ]Each adverse event must be graded as the worst grade observed during the entire treatment period of each treatment protocol according to Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0) up to 1 year.
- Serious adverse events [ Time Frame: Up to 1 year after completion/termination of the protocol treatment. ]Each serious adverse event must be recorded according to CTCAE v4.0 up to 1 year.
- Progression-free survival (PFS) from bevacizumab (BEV) initiation [ Time Frame: Time to event from initiation of BEV. Up to 2 years from the last patient in. ]Progression free from BEV initiation will be measured from the day of initiation of BEV until the first occurrence of progression or death.
- 6-month progression-free survival (6m-PFS) after initiation of bevacizumab (BEV) (Experimental Arm Only) [ Time Frame: 6 months from initiation of BEV ]Number of patients without progression at 6 months from the day of initiation of BEV divided by number of all second-line (BEV) treated in Experimental Arm
- Overall survival after initiation of bevacizumab (BEV) [ Time Frame: Time to event from initiation of BEV. Up to 2 years from the last patient in. ]Overall survival from the day of initiation of BEV until death for any reason. If the patient is alive at last follow-up, the patient will be censored at the last time of confirmation of survival.
- MMSE non-deterioration rate [ Time Frame: MMSE non-deterioration rates will be calculated at 8 and 24 weeks after initiation of protocol treatment ]The MMSE (Mini Mental Status Examination) non-deterioration rate is calculated from the number of patients who underwent baseline MMSE evaluation prior to initiation of protocol treatment as a denominator and the number of those whose MMSE score (normal (30-24), mild decrease (23-20), intermediate decrease (19-10), severe decrease (9-0)) at 16 weeks improved or maintained from that at baseline as a numerator among all eligible patients.
- KPS non-deterioration rate [ Time Frame: KPS non-deterioration rates will be calculated at 8 and 24 weeks after initiation of protocol treatment ]The KPS non-deterioration rate is calculated from the number of patients whose KPS was recorded prior to initiation of protocol treatment as a denominator and the number of those whose KPS score at 16 weeks improved or maintained from that at baseline as a numerator among all eligible patients. In case KPS is not recorded, it is considered as deterioration.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 20 Years to 75 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Histologically proven diagnosis of glioblastoma (including giant cell glioblastoma and gliosarcoma) by WHO2007 criteria.
- For patients who did not undergo surgery for recurrent disease; pre-registration contrast MRI should confirm; (i)progressive or recurrent glioblastoma; (ii)no evidence of acute or subacute cerebral hemorrhage at enrolment; (iii)presence of a measurable lesion.
- For patients who underwent surgery for recurrent disease; (i)progressive or recurrent glioblastoma must be confirmed on contrast MRI before reoperation; (ii)glioblastoma or anaplastic astrocytoma must be histologically identified in the tissue resected at reoperation; (iii)presence of measurable lesions is not mandatory on pre-registration contrast MRI (more than 4 days after reoperation); (iv)no MRI evidence of aggravating cerebral hemorrhage.
- No evidence of tumors in the cerebellum, brain stem, optic nerve, olfactory nerve, and pituitary gland.
- No evidence of meningeal dissemination or gliomatosis cerebri.
- Prior treatment for newly-diagnosed glioblastoma (or diffuse astrocytoma (Grade II) or anaplastic astrocytoma (Grade III)) with postoperative TMZ administered concomitantly with radiotherapy (>=54 Gy for <=69 years old; >=30 Gy for >=70 years old) and at least for two cycles (5/28d) as an adjuvant treatment have been given.
-
No history of prior treatment with stereotactic radiotherapy (ex. Gamma-knife/Cyberknife), proton beam irradiation, neutron capture therapy, and chemotherapies except standard dose TMZ and immunotherapy (vaccines, immune checkpoint inhibitors, antibodies etc.), bevacizumab (12 weeks or more after termination of prior upfront bevacizumab use) that were combined with TMZ, and intraoperative placement of carmustine wafers, for glioblastoma (including diffuse astrocytoma (Grade II) and anaplastic astrocytoma (Grade III) at onset) diagnosed with WHO2007 criteria.
Time periods required from the last day of the prior treatment indicated at registration.
①Peptide vaccination, immune checkpoint inhibitors, antibodies: 4 weeks.
②Bevacizumab: 12 weeks.
- More than 90 days after completion of radiotherapy. For those who underwent reoperation, between 21 and 28 days postoperatively.
- Age between 20 and 75 years at enrolment.
- Karnofsky Performance Status >= 60 within 14 days before enrolment.
- No prior treatment with chemotherapy, molecular targeted therapy, or radiotherapy to head and neck area for other malignancies.
- Adequate organ function.
- Written informed consent.
Exclusion Criteria:
- Synchronous or metachronous (within 5 years) malignancy, except for carcinoma in situ or mucosal tumors curatively treated with local therapy
- Active infection requiring systemic therapy
- Body temperature >= 38 degrees Celsius at registration
- Women during pregnancy, possible pregnancy, within 28 days after delivery, or breast-feeding
- Psychosis or with psychotic symptom
- Continuous systemic use of immunosuppressant except for steroid
- Uncontrolled diabetes mellitus or routine administration of insulin
- Unstable angina within 3 weeks, with a history of myocardial infarction within 6 months, or New York Heart Association (NYHA) class II or greater congestive heart failure
- Inadequately controlled hypertension (cannot be controlled to a systolic pressure of >= 150 mmHg and a diastolic pressure of >= 100 mmHg)
- History of symptomatic cerebrovascular disorder (including subarachnoid hemorrhage, cerebral infarction and transient ischemic attack) within 6 months or history of vascular disorder requiring intervention (including venous/arterial thrombosis or embolism and aortic aneurysm) within 6 moths
- History of grade >= 2 hemoptysis within 28 days
- History of hemorrhagic tendency (e.g., coagulation disorder) or any grade >= 3 hemorrhage within 28 days
- History of gastrointestinal perforation, fistula, abdominal abscess or uncontrolled peptic ulcer within 6 months
- Interstitial pneumonia, pulmonary fibrosis, or severe lung emphysema
- Severe non-healing wound or traumatic fracture at enrolment
- Hypersensitivity to Chinese Hamster Ovary-derived drugs or other recombinant antibodies
- Gadolinium allergy
- Positive HIV antibody
- Positive Hepatitis B (HB)s antigen
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02761070
| Contact: Motoo Nagane, M.D., Ph.D. | +81-422-47-5511 ext 2883 | mnagane@ks.kyorin-u.ac.jp | |
| Contact: Keiichi Kobayashi, M.D., Ph.D. | +81-422-47-5511 ext 2883 | kekobayashi@kki.biglobe.ne.jp |
Show 37 study locations
| Study Chair: | Motoo Nagane, M.D., Ph.D. | Kyorin University Faculty of Medicine, Department of Neurosurgery |
| Responsible Party: | Motoo Nagane, Professor, Kyorin University |
| ClinicalTrials.gov Identifier: | NCT02761070 |
| Other Study ID Numbers: |
JCOG1308C |
| First Posted: | May 4, 2016 Key Record Dates |
| Last Update Posted: | September 1, 2020 |
| Last Verified: | August 2020 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
|
glioblastoma recurrent dose-dense temozolomide bevacizumab |
|
Glioblastoma Recurrence Astrocytoma Glioma Neoplasms, Neuroepithelial Neuroectodermal Tumors Neoplasms, Germ Cell and Embryonal Neoplasms by Histologic Type Neoplasms Neoplasms, Glandular and Epithelial Neoplasms, Nerve Tissue Disease Attributes Pathologic Processes |
Bevacizumab Temozolomide Antineoplastic Agents, Immunological Antineoplastic Agents Angiogenesis Inhibitors Angiogenesis Modulating Agents Growth Substances Physiological Effects of Drugs Growth Inhibitors Antineoplastic Agents, Alkylating Alkylating Agents Molecular Mechanisms of Pharmacological Action |